First-in-Human Trial of VBC108 for Advanced Solid Tumors
This study is testing a new drug called VBC108 for people with advanced solid tumors that cannot be removed by surgery or have spread. This is the first time VBC108 is being given to humans. The study aims to find the safest and most effective dose of VBC108. To join, you must be at least 18 years old and have a confirmed advanced solid tumor that can be measured. The main goals are to track any serious side effects (adverse events) and side effects that limit the dose (dose-limiting toxicities) of VBC108.
- Study design
- This is an open-label (you and your doctors will know what treatment you are receiving) study with multiple doses, planning to enroll 230 participants. It has two parts: Phase 1 to find the best dose, and Phase 2a to confirm safety and effectiveness.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be monitored for serious side effects and other adverse events from the time you give consent until 30 days after your last dose of VBC108.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
At a glance
Conditions
NCT07700160
Where you'd take part
This study runs at 12 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Beijing Cancer Hospital
Beijing, Beijing Municipality, Chinastudy coordinator listed
Not yet recruiting
Beijing GoBroad Hospital
Beijing, Beijing Municipality, Chinastudy coordinator listed
Not yet recruiting
City of Hope Medical Center
Duarte, Californiastudy coordinator listed
Recruiting
GenesisCare North Shore
St Leonards, New South Wales, Australiastudy coordinator listed
Recruiting
Laura and Issac Perlmutter Cancer Center
New York, New Yorkstudy coordinator listed
Not yet recruiting
Next Oncology - Oncology
San Antonio, Texasstudy coordinator listed
Recruiting
NEXT Oncology Virginia
Fairfax, Virginiastudy coordinator listed
Recruiting
One Clinical Research
Perth, Western Australia, Australiastudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of dose-limiting toxicities (DLT) as defined in the protocolFrom time of first dose of VBC108 to end of DLT period ( 21 days)
Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
- Incidence of Serious Adverse EventsFrom time of Informed Consent to 30 days post last dose of VBC108
Number of patients with serious adverse events by system organ class and preferred term
- Incidence of Adverse Events (AEs)From time of Informed Consent to 30 days post last dose of VBC108
Number of patients with adverse events by system organ class and preferred term
- Objective Response Rate (ORR)From first dose of VBC108 to disease progression or death, up to approximately 2 years
The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)